BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Galcanezumab (Emgality) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Galcanezumab (Emgality)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07323927-10393@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Galcanezumab (Emgality): Phase 1 readout est. (NCT07323927)
DESCRIPTION:Galcanezumab (Emgality)\, phase 1.\nStudy: Investigator Initiat
 ed Trial of Galcanezumab Treatment in Alzheimer's Disease\nEstimated prima
 ry completion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/galcanezumab-emgality#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07323927
URL:https://assetmemo.bio/drug/galcanezumab-emgality#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07655440-10393@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Galcanezumab (Emgality): Phase 4 readout est. (NCT07655440)
DESCRIPTION:Galcanezumab (Emgality)\, phase 4\, Migraine.\nStudy: Comparing
  Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Pat
 ients With Migraine (COMPACT-PM)\nEstimated primary completion: July 2031.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/galcanezumab-emgalit
 y#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 655440
URL:https://assetmemo.bio/drug/galcanezumab-emgality#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
